Celina M. Scally Sells 1,314 Shares of Apria, Inc. (NYSE:APR) Stock

Apria, Inc. (NYSE:APR) SVP Celina M. Scally sold 1,314 shares of the stock in a transaction dated Monday, September 13th. The stock was sold at an average price of $37.08, for a total value of $48,723.12. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

APR opened at $37.16 on Wednesday. The company has a debt-to-equity ratio of 215.95, a current ratio of 1.21 and a quick ratio of 1.18. The company’s 50 day simple moving average is $32.37 and its two-hundred day simple moving average is $29.35. Apria, Inc. has a 1-year low of $20.07 and a 1-year high of $38.47. The firm has a market capitalization of $1.31 billion and a price-to-earnings ratio of 0.80.

Apria (NYSE:APR) last released its earnings results on Thursday, August 5th. The company reported $0.54 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.37 by $0.17. On average, equities analysts anticipate that Apria, Inc. will post 1.63 earnings per share for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the company. Northern Trust Corp purchased a new stake in shares of Apria during the 1st quarter valued at approximately $2,404,000. HBK Investments L P purchased a new stake in shares of Apria during the 1st quarter valued at approximately $1,397,000. Oliver Luxxe Assets LLC purchased a new stake in shares of Apria during the 2nd quarter valued at approximately $435,000. Parian Global Management LP purchased a new stake in shares of Apria during the 1st quarter valued at approximately $1,397,000. Finally, Fred Alger Management LLC purchased a new stake in shares of Apria during the 1st quarter valued at approximately $4,429,000. 94.99% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities research analysts have recently commented on the company. Piper Sandler raised their target price on Apria from $33.00 to $35.00 and gave the company an “overweight” rating in a research report on Friday, August 6th. assumed coverage on shares of Apria in a research note on Wednesday, June 30th. They issued a “buy” rating and a $33.00 price target on the stock. Zacks Investment Research raised shares of Apria from a “hold” rating to a “buy” rating and set a $35.00 price target on the stock in a research note on Tuesday, August 10th. The Goldman Sachs Group lowered shares of Apria from a “buy” rating to a “neutral” rating and decreased their price target for the company from $32.00 to $29.00 in a research note on Monday, July 19th. Finally, Citigroup raised their price target on shares of Apria from $33.00 to $38.00 and gave the company a “buy” rating in a research note on Friday, August 6th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $31.86.

About Apria

Apria, Inc provides integrated home healthcare equipment and related services in the United States. The company offers home respiratory therapies, including the supply of stationary and portable home oxygen equipment, and non-invasive ventilators; obstructive sleep apnea therapy devices comprising continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services; and negative pressure wound therapy products.

Recommended Story: Most Volatile Stocks

Receive News & Ratings for Apria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apria and related companies with MarketBeat.com's FREE daily email newsletter.